These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15133531)

  • 1. Urinary excretion of rifampicin in the presence of ciprofloxacin.
    Orisakwe OE; Afonne OJ; Agbasi PU; Ofoefule SI
    Am J Ther; 2004; 11(3):171-4. PubMed ID: 15133531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pefloxacin on the urinary excretion of rifampicin.
    Orisakwe OE; Agbasi PU; Ofoefule SI; Ilondu NA; Afonne OJ; Anusiem CA; Ilo CE; Maduka SO
    Am J Ther; 2004; 11(1):13-6. PubMed ID: 14704591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin pharmacokinetics with and without ciprofloxacin.
    Orisakwe OE; Agbasi PU; Afonne OJ; Ofoefule SI; Obi E; Orish CN
    Am J Ther; 2001; 8(3):151-3. PubMed ID: 11344382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin.
    Nielsen K; Bangsborg JM; Høiby N
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):43-8. PubMed ID: 10744366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failures of rifampicin and ciprofloxacin to eradicate a susceptible meningococcal isolate from a close contact of a fatal case.
    Tsakris A; Trakatelli C; Souliou E; Sofianou D; Ntoutsou K; Antoniadis A
    Infection; 2001 Oct; 29(5):293-4. PubMed ID: 11688913
    [No Abstract]   [Full Text] [Related]  

  • 8. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin.
    Orisakwe OE; Akunyili DN; Agbasi PU; Ezejiofor NA
    Am J Ther; 2004; 11(4):283-7. PubMed ID: 15266220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila.
    Onody C; Matsiota-Bernard P; Nauciel C
    J Antimicrob Chemother; 1997 Jun; 39(6):815-6. PubMed ID: 9222053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin causes false-positive immunoassay results for urine opiates.
    de Paula M; Saiz LC; González-Revaldería J; Pascual T; Alberola C; Miravalles E
    Clin Chem Lab Med; 1998 Apr; 36(4):241-3. PubMed ID: 9638350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 12. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the in vivo post-antibiotic effects of ciprofloxacin and rifampicin.
    Meng X; Pei Y; Nightingale CH; Quintiliani R
    J Antimicrob Chemother; 1995 Dec; 36(6):987-96. PubMed ID: 8821597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics.
    Moffie BG; Mouton RP
    J Antimicrob Chemother; 1988 Oct; 22(4):457-62. PubMed ID: 3204075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenomenon of rifampicin-induced discolouration of body fluids.
    Morgan JR; Clarke KW; Brear SG
    Respir Med; 1993 May; 87(4):320-1. PubMed ID: 9728237
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
    Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ
    Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients.
    Jaruratanasirikul S; Kleepkaew A
    J Antimicrob Chemother; 1996 Nov; 38(5):877-80. PubMed ID: 8961059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.